文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Lenzumestrocel(Neuronata-R®注射液)治疗肌萎缩侧索硬化患者的疗效与安全性(ALSUMMIT研究):多中心、随机、双盲、平行组、假操作对照III期试验的研究方案

Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial.
PubMed 文献 · Trials · 2022-05-18

ALSUMMIT是一项多中心、随机、双盲、平行组、假操作对照的III期试验,计划纳入115例肌萎缩侧索硬化患者,按1:2:2随机分为单周期组、单周期+3次加强注射组和对照组。主要终点采用联合功能与生存评估(CAFS,即联合秩评分JRS),分别在首次给药后6个月(单周期组 vs 对照组)和12个月(加强组 vs 对照组)评估,安全性评估贯穿研究全程。

要点

  • ALSUMMIT为III期多中心随机双盲假操作对照试验,计划纳入115例ALS患者。
  • 受试者按1:2:2随机分为单周期组、单周期+3次加强注射组和对照组。
  • 主要终点为首次给药后6个月和12个月的功能与生存联合评估(CAFS/JRS)。

核心结论

  • 该方案旨在评估单周期鞘内注射联合三次加强注射BM-MSC(Lenzumestrocel)治疗ALS的长期疗效与安全性。
  • Lenzumestrocel是韩国食品医药品安全处(MFDS)附条件批准的孤儿细胞治疗产品。
  • 研究采用富集入组、附加设计和考虑对照组伦理问题的方案设计。

研究设计与样本

  • ALSUMMIT为多中心、随机、双盲、平行组、假操作对照的III期试验。
  • 计划纳入115例受试者,按1:2:2随机分为三组:研究1组(单周期,两次重复注射,间隔26天)、研究2组(单周期+在第4、7、10个月三次加强注射)和对照组。
  • 纳入疾病进展速度中等的参与者以减少临床异质性。
  • 主要终点为首次给予Lenzumestrocel或安慰剂后6个月(研究1组 vs 对照组)和12个月(研究2组 vs 对照组)的功能与生存联合评估(CAFS,即联合秩评分JRS)。
  • 安全性评估贯穿整个研究期间;56周主要研究结束后进行长期随访观察性研究,评估长达36个月的长期疗效与安全性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A single cycle (two repeated treatments) with intrathecal autologous bone marrow-derived mesenchymal stem cells (BM-MSCs, 26-day interval) showed safety and provided therapeutic benefit lasting 6 months in patients with ALS but did not demonstrate long-term efficacy. This phase III clinical trial (ALSUMMIT) protocol was developed to evaluate the long-term efficacy and safety of the combined protocol of single-cycle intrathecal therapy and three additional booster injections of BM-MSC (Lenzumestrocel) treatment in patients with ALS. METHODS: ALSUMMIT is a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial for ALS. The 115 subjects will be randomized (1:2:2) into three groups: (1) study Group 1 (single-cycle, two repeated injections with 26-day interval), (2) study Group 2 (single-cycle + three additional booster injections at 4, 7, and 10 months), and (3) the control group. Participants who have an intermediate rate of disease progression will be included in this trial to reduce clinical heterogeneity. The primary endpoint will be evaluated by combined assessment of function and survival (CAFS), also known as joint rank scores (JRS), at 6 months (study Group 1 vs. control) and 12 months (study Group 2 vs. control) after the first Lenzumestrocel or placebo administration. Safety assessment will be performed throughout the study period. Additionally, after the 56-week main study, a long-term follow-up observational study will be conducted to evaluate the long-term efficacy and safety up to 36 months. DISCUSSION: Lenzumestrocel is the orphan cell therapy product for ALS conditionally approved by the South Korea Ministry of Food and Drug Safety (MFDS). This ALSUMMIT protocol was developed for the adoption of enrichment enrolment, add-on design, and consideration of ethical issues for the placebo group. TRIAL REGISTRATION: ClinicalTrials.gov NCT04745299 . Registered on Feb 9, 2021. Clinical Research Information Service (CRIS) KCT0005954 . Registered on Mar 4, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Nam JY, Lee TY, Kim K, et al. Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial. Trials. 2022. PMID: 35585556. doi:10.1186/s13063-022-06327-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。